CN116036068A - 蓝萼l素在制备预防或治疗非酒精性脂肪肝炎药物中的应用 - Google Patents
蓝萼l素在制备预防或治疗非酒精性脂肪肝炎药物中的应用 Download PDFInfo
- Publication number
- CN116036068A CN116036068A CN202310268362.8A CN202310268362A CN116036068A CN 116036068 A CN116036068 A CN 116036068A CN 202310268362 A CN202310268362 A CN 202310268362A CN 116036068 A CN116036068 A CN 116036068A
- Authority
- CN
- China
- Prior art keywords
- glaucocalyxin
- liver
- preventing
- medicament
- nash
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930183427 glaucocalyxin Natural products 0.000 title claims abstract description 45
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title claims abstract description 37
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 229940079593 drug Drugs 0.000 title abstract description 8
- 210000004185 liver Anatomy 0.000 claims abstract description 21
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 15
- 206010061218 Inflammation Diseases 0.000 claims abstract description 8
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- 230000008021 deposition Effects 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 abstract description 4
- 201000007270 liver cancer Diseases 0.000 abstract description 4
- 208000014018 liver neoplasm Diseases 0.000 abstract description 4
- 230000004761 fibrosis Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002300 anti-fibrosis Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241001183967 Isodon Species 0.000 description 1
- 241000554432 Isodon amethystoides Species 0.000 description 1
- 238000013231 NASH rodent model Methods 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical compound CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供了蓝萼L素在制备预防或治疗非酒精性脂肪肝炎药物中的应用,属于医药技术领域。本发明提供的蓝萼L素能够有效缓解NASH的相关症状,减轻NASH患者肝脏的炎症和纤维化水平,降低其发展为肝硬化、肝癌的风险,具有很大潜力作为缓解非酒精性脂肪性肝炎的特效药物。
Description
技术领域
本发明属于医药技术领域,尤其涉及蓝萼L素在制备预防或治疗非酒精性脂肪肝炎药物中的应用。
背景技术
非酒精性脂肪性肝炎(nonalcoholic steatohepatitis,NASH)是一种较常见的慢性肝病。非酒精性脂肪性肝炎(NASH)显著提高患者发展成肝硬化、肝衰竭以及肝癌的风险,是一种潜在的致命性疾病。近年来NASH发病率快速上升,但其发病机制尚未完全明确。应用于临床试验的治疗药物不良反应较多,所以目前尚未有药物获批用于NASH。
发明内容
有鉴于此,本发明的目的在于提供蓝萼L素在制备预防或治疗非酒精性脂肪肝炎药物中的应用。本发明提供的蓝萼L素能够有效缓解NASH的相关症状,减轻NASH患者肝脏的炎症和纤维化水平,降低其发展为肝硬化、肝癌的风险,具有很大潜力作为缓解非酒精性脂肪性肝炎的特效药物。
为了实现上述发明目的,本发明提供了以下技术方案:
本发明提供了蓝萼L素在制备预防或治疗非酒精性脂肪肝炎药物中的应用。
优选的,所述应用为在制备减轻高脂肝脏的脂肪沉积和炎症药物中的应用。
优选的,所述应用为在制备降低肝脏纤维化水平药物中的应用。
优选的,所述药物还包括药学上可接受的辅料和/或载体。
优选的,所述药物的剂型包括片剂、胶囊剂、颗粒剂、丸剂或口服溶液中的任意一种。
本发明还提供了一种用于预防或治疗非酒精性脂肪肝炎的药物,包含有效量的蓝萼L素。
本发明将蓝萼L素作用在小鼠NASH模型上,蓝萼L素可有效减轻高脂小鼠肝脏的脂肪沉积和炎症,显著缓解肝损伤水平。同时,蓝萼L素可有效降低肝脏纤维化水平,具有强烈的抗炎、抗纤维化作用。因此,蓝萼L素能够有效缓解NASH的相关症状,减轻NASH患者肝脏的炎症和纤维化水平,降低其发展为肝硬化、肝癌的风险。
附图说明
图1为H&E染色检测肝脏炎性细胞浸润情况;
图2为天狼猩红染色检测肝脏纤维化情况;
图3为油红O染色检测肝脏脂肪沉积情况;
图4蓝萼L素缓解NASH小鼠的肝纤维化;
图5蓝萼L素缓解NASH小鼠肝脏炎症基因的表达。
具体实施方式
本发明提供了蓝萼L素在制备预防或治疗非酒精性脂肪肝炎药物中的应用。
本发明对所述蓝萼L素的来源没有特殊限定,采用常规市售的产品或者从香茶菜中药中分离提取得到的蓝萼L素均可。本发明对从香茶菜中药中分离提取蓝萼L素的方法没有特殊限定,采用本领域的常规提取分离方法即可。
在本发明中,所述蓝萼L素可有效减轻高脂肝脏的脂肪沉积和炎症,显著缓解肝损伤水平。
在本发明中,所述蓝萼L素可有效降低肝脏纤维化水平,具有强烈的抗炎、抗纤维化作用。
在本发明中,所述药物还包括药学上可接受的辅料和/或载体。本发明对所述的辅料或载体没有特殊的限定,采用常规制药领域的辅料或载体即可。
在本发明中,所述药物的剂型包括片剂、胶囊剂、颗粒剂、丸剂或口服溶液中的任意一种。
本发明还提供了一种用于预防或治疗非酒精性脂肪肝炎的药物,包含有效量的蓝萼L素。
下面结合实施例对本发明提供的技术方案进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
实施例1
1.CDAHFD饮食诱导小鼠非酒精性脂肪性肝炎
6周龄雄性C57BL/6小鼠随机分为四组:正常对照组、模型对照组、蓝萼L素低剂量组和蓝萼L素高剂量组。正常对照组使用普通饲料喂养。模型对照组、蓝萼L素低剂量组和蓝萼L素高剂量组使用CDAHFD高脂饲料喂养,连续喂养8周,建立非酒精性脂肪性肝炎模型。8周后,蓝萼L素低剂量组和蓝萼L素高剂量组使用蓝萼L素灌胃4周(低剂量组:10mg/kg,高剂量组:50mg/kg)。
1.1苏木素伊红(H&E)染色
水化后的肝脏组织切片,用纯净水浸润3min,重复3次。滴加适量苏木素染色5min,流水冲洗,适量1%盐酸酒精分化5s,流水冲洗,0.6%氨水返蓝,再次冲洗。控干水分,伊红染液染30s,流水冲洗,干燥处理,中性树胶封片,显微镜镜检,采集图像分析。
1.2天狼猩红(sirius red)染色
天狼猩红染色切片常规脱蜡至水,天狼猩红-苦味酸饱和溶液染30min左右,无水乙醇分化脱水,中性树胶封片,显微镜镜检,采集图像分析。
1.3油红O(oil red O)染色
取出液氮保存的肝组织,剪成2cm大小组织块,放入特制小盒。适量OTC包埋,盒子底部接触液氮,待10s后组织冰冻成块,制成6μm厚度的冰冻切片。流水稍冲洗切片,60%异丙醇浸洗2min,油红O染液染5min,60%异丙醇再次浸洗,纯净水冲洗掉多余的异丙醇,苏木素复染1min,盐酸酒精分化5s,流水反蓝,吸去多余水分后,甘油封片,显微镜镜检,采集图像分析。
2.结果
2.1蓝萼L素对肝脏炎性细胞浸润的影响
H&E染色结果显示,正常对照组的小鼠肝脏显示肝小叶排列整齐,无坏死和脂肪空泡。而在CDAHFD诱导的小鼠非酒精性脂肪肝炎模型对照组中,肝脏脂肪沉积、炎性细胞浸润。蓝萼L素干预治疗后肝小叶结构趋于恢复正常,坏死细胞明显减少,脂肪空泡缩小,并且伴随剂量依赖性(图1)。
2.2蓝萼L素对肝脏纤维化的影响
天狼猩红染色结果显示,正常对照组的小鼠肝脏未见纤维增生。而在CDAHFD诱导的小鼠非酒精性脂肪肝炎模型对照组中,肝脏纤维增生明显,可见明显染色成红色的纤维间隔。蓝萼L素干预治疗后纤维间隔明显减少,并且伴随剂量依赖性(图2)。
2.3蓝萼L素对肝脏脂肪沉积的影响
油红O染色结果显示,正常对照组的小鼠肝脏细胞形态正常,只可见蓝色细胞核,无脂滴存在。而在CDAHFD诱导的小鼠非酒精性脂肪肝炎模型对照组中,肝脏可见明显红色脂滴。蓝萼L素干预治疗后纤维间隔明显减少,并且伴随剂量依赖性(图3)。
2.4蓝萼L素对肝脏纤维化相关基因蛋白表达的影响
α-SMA和TGFβ是肝脏纤维化的相关基因。qPCR对这些基因的mRNA水平进行检测。结果显示,与正常对照相比,CDAHFD诱导的模型对照组可上调α-SMA和TGFβ表达水平(P<0.05)。与模型对照相比,蓝萼L素可逆转其上调(图4,P<0.05;图4蓝萼L素缓解NASH小鼠的肝纤维化;小鼠肝脏TGFβ和α-SMA的mRNA表达水平;数据分析采用平均值±标准差,n=6。*,P<0.05vs.正常对照组;#,P<0.05vs.模型对照组。)。说明蓝萼L素具有抗纤维化作用。
2.5蓝萼L素对炎症因子相关基因mRNA的影响
TNFα、IL-6和iNOS是炎症相关的基因。qPCR检测发现,与正常对照相比,CDAHFD诱导的模型对照组肝脏内这些炎症相关基因的表达上调。蓝萼L素干预治疗后,该上调趋势可被逆转,且逆转具有浓度依赖性(图5,P<0.05;图5蓝萼L素缓解NASH小鼠肝脏炎症基因的表达。小鼠肝脏TNFα、IIL-6和iNOS的mRNA表达水平,数据分析采用平均值±标准差,n=6。*,P<0.05vs.正常对照组;#,P<0.05vs.模型对照组。)。说明蓝萼L素具有很强的抗炎作用。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (6)
1.蓝萼L素在制备预防或治疗非酒精性脂肪肝炎药物中的应用。
2.根据权利要求1所述的应用,其特征在于,所述应用为在制备减轻高脂肝脏的脂肪沉积和炎症药物中的应用。
3.根据权利要求1所述的应用,其特征在于,所述应用为在制备降低肝脏纤维化水平药物中的应用。
4.根据权利要求1所述的应用,其特征在于,所述药物还包括药学上可接受的辅料和/或载体。
5.根据权利要求1所述的应用,其特征在于,所述药物的剂型包括片剂、胶囊剂、颗粒剂、丸剂或口服溶液中的任意一种。
6.一种用于预防或治疗非酒精性脂肪肝炎的药物,其特征在于,包含有效量的权利要求1所述的蓝萼L素。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310268362.8A CN116036068B (zh) | 2023-03-20 | 2023-03-20 | 蓝萼l素在制备预防或治疗非酒精性脂肪肝炎药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310268362.8A CN116036068B (zh) | 2023-03-20 | 2023-03-20 | 蓝萼l素在制备预防或治疗非酒精性脂肪肝炎药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116036068A true CN116036068A (zh) | 2023-05-02 |
CN116036068B CN116036068B (zh) | 2024-05-24 |
Family
ID=86125862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310268362.8A Active CN116036068B (zh) | 2023-03-20 | 2023-03-20 | 蓝萼l素在制备预防或治疗非酒精性脂肪肝炎药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116036068B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103800314A (zh) * | 2014-01-24 | 2014-05-21 | 中国人民解放军第二军医大学 | 蓝萼l素在制药中的应用 |
-
2023
- 2023-03-20 CN CN202310268362.8A patent/CN116036068B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103800314A (zh) * | 2014-01-24 | 2014-05-21 | 中国人民解放军第二军医大学 | 蓝萼l素在制药中的应用 |
Non-Patent Citations (3)
Title |
---|
刘洪川等: "蓝曹香茶菜化学成分及抗肿瘤和抗乙肝病毒作用研究", 中国医药教育协会第三届三次理事大会暨学术年会论文专辑, 10 November 2013 (2013-11-10) * |
欧阳思露等: "基于网络药理学探讨冬凌草抗癌的活性成分及作用机制", 中华中医药学刊, vol. 39, no. 4, 30 April 2021 (2021-04-30) * |
苏永庆等: "蓝萼香茶菜萜类和黄酮类化合物的研究新进展", 中国野生植物资源, vol. 36, no. 3, 30 June 2017 (2017-06-30) * |
Also Published As
Publication number | Publication date |
---|---|
CN116036068B (zh) | 2024-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104288356B (zh) | 治疗奶牛乳房炎的中药灌注液及其制备方法 | |
CN103446525B (zh) | 治疗皮肤病的中药组合物及其制备方法和应用 | |
CN111568948A (zh) | 桑提取物在制备改善胰岛功能药物中的应用 | |
CN116036068B (zh) | 蓝萼l素在制备预防或治疗非酒精性脂肪肝炎药物中的应用 | |
CN107137450B (zh) | 一种药物组合物及其应用 | |
CN110025664B (zh) | 用于防治脑梗死和/或血管性痴呆的药物组合物及其应用 | |
US10195240B2 (en) | Composition for preventing or treating oxidative brain damage and brain dysfunction, and production method for same | |
CN1895623A (zh) | 一种治疗脂肪肝的药物组合物及制备方法和应用 | |
CN109925445A (zh) | 金线莲提取物在制备预防和/或治疗d-氨基半乳糖致小鼠急性肝损伤药物中的应用 | |
CN111840331B (zh) | 一种熊胆外泌体在制备治疗ii型糖尿病药物中的应用 | |
CN114601865A (zh) | 桑提取物在制备治疗溃疡性结肠炎的药物中的应用 | |
CN104257676B (zh) | 一种治疗虚寒型偏头痛的组合物 | |
CN102247349B (zh) | 丹酚酸a预防和/或治疗糖尿病所致肝脏病变的用途 | |
CN105233255A (zh) | 一种用于病理性脱发的中西药复方护理剂及其制备方法 | |
CN117085006B (zh) | 丹酚酸y制备治疗荨麻疹药物中的应用 | |
CN1679600A (zh) | 人参皂苷c-k在制备治疗或预防肝纤维化的药物中的应用 | |
CN1243443A (zh) | 用于增殖双歧杆菌的鲜地黄提取物及其提取方法 | |
CN115671219B (zh) | 一种治疗痛风的中药组合物及其制备方法和应用 | |
CN115624543B (zh) | 治疗偏头痛的药物、药物组合物、其制备方法和制药用途 | |
CN110292577B (zh) | 泮托拉唑在制备防治非酒精性脂肪肝的药物中的应用 | |
CN108403881A (zh) | 一种治疗老年痴呆的药物组合物及其制备方法与用途 | |
CN108355027A (zh) | 一种中草药萃取物及其用于制备治疗三阴性乳腺癌的药物的用途 | |
AU2021105573A4 (en) | Application of emodin in inhibiting the proliferation of alcohol-induced activated hepatic stellate cells in the treatment of liver fibrosis | |
CN115364142B (zh) | 芪冬颐心口服液在制备治疗糖尿病心肌病的药物中的应用 | |
CN102406790A (zh) | 一种治疗乳腺增生疾病的中药胶囊及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |